Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases

Journal of Rheumatology

Volumn 42, Issue 9, 2015, Pages 1661-1666

  Yilmaz, Neslihan ^a   Emmungil, Hakan ^b   Gucenmez, Sercan ^b   Ozen, Gulsen ^c   Yildiz, Fatih ^d   Balkarli, Aye ^e   Kimyon, Gezmis ^f   Coskun, Belkis Nihan ^g   Dogan, Ismail ^h   Pamuk, Omer Nuri ⁱ   Yasar, Sule ^j   Cetin, Gozde Yildirim ^k   Yazici, Ayten ^l   Esmen, Serpil Ergulu ^m   Cagatay, Yonca ^a   Yilmaz, Sema ^m   Cefle, Ayse ^l   Sayarlioglu, Mehmet ^k   Kasifoglu, Timucin ^j   Karadag, Omer ^h   Pehlivan, Yavuz ^g   Dalkilic, Ediz ^g   Kisacik, Bunyamin ^f   Cobankara, Veli ^e   Erken, Eren ^d   Direskeneli, Haner ^c   Aksu, Kenan ^b   Yavuz, Sule ^b   more..

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^e PAMUKKALE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^f Gaziantep Blood Center   (Turkey)

^g ULUDAG UNIVERSITY   (Turkey)

^h HACETTEPE UNIVERSITY   (Turkey)

ⁱ TRAKYA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^j Eski ehir Osmangazi University   (Turkey)

^k KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

^l KOCAELI UNIVERSITY   (Turkey)

^m SELCUK UNIVERSITY FACULTY OF MEDICINE   (Turkey)

more..

Author keywords

Hemorrhagic cystitis; Mesna; Rheumatic diseases

Indexed keywords

CYCLOPHOSPHAMIDE; MESNA; PROTECTIVE AGENT;

ADULT; ARTICLE; BLADDER CANCER; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT OUTCOME; VASCULITIS; AGED; CHEMICALLY INDUCED; CYSTITIS; INCIDENCE; MIDDLE AGED; RHEUMATIC DISEASES;

ADULT; AGED; CYCLOPHOSPHAMIDE; CYSTITIS; FEMALE; HUMANS; INCIDENCE; MALE; MESNA; MIDDLE AGED; PROTECTIVE AGENTS; RHEUMATIC DISEASES; TREATMENT OUTCOME;

EID: 84940707172     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150065     Document Type: Article

References (44)

1. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 2010;62:9-21.
2. Aptekar RG, Atkinson JP, Decker JL, Wolff SM, Chu EW. Bladder toxicity with chronic oral cyclophosphamide therapy in nonmalignant disease. Arthritis Rheum 1973;16:461-7.
3. Plotz PH, Klippel JH, Decker JL, Grauman D, Wolff B, Brown BC, et al. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 1979;91:221-3.
4. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-84.
5. Pedersen-Bjergaard J, Ersboll J, Hansen VL, Sorensen BL, Christoffersen K, Hou-Jensen K, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988;318:1028-32.
6. Mirkes PE. Cyclophosphamide teratogenesis: a review. Teratog Carcinog Mutagen 1985;5:75-88.
7. Wetzels JF. Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? Neth J Med 2004;62:347-52.
8. Martin F, Lauwerys B, Lefèbvre C, Devogelaer JP, Houssiau FA. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997;6:254-7.
9. Brock N. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds. Cancer Treat Rep 1976;60:301-8.
10. Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung 1979;29:659-61.
11. Batista CK, Brito GA, Souza ML, Leitao BT, Cunha FQ, Ribeiro RA. A model of hemorrhagic cystitis induced with acrolein in mice. Braz J Med Biol Res 2006;39:1475-81.
12. Mesna. In: Dorr RT, Von Hoff DD, eds. Cancer chemotherapy handbook, 2nd ed. Norwalk: Appleton & Lange; 1994: 685-91.
13. Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991;42:428-67.
14. Scheef W, Klein HO, Brock N, Burkert H, Gunther U, Hoefer-Janker H, et al. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep 1979;63:501-5.
15. Bryant BM, Jarman M, Ford HT, Smith IE. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 1980;2:657-9.
16. Sakurai M, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, et al. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. Jpn J Clin Oncol 1986;16:153-6.
17. Fukuoka M, Negoro S, Masuda N, Furuse K, Kawahara M, Kodama N, et al. Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 1991;117:473-8.
18. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17:3333-55.
19. Stillwell TJ, Benson RC Jr, DeRemee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988;31:465-70.
20. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:102-32
21. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990;89:403-10.
22. Koldingsnes W, Gran JT, Omdal R, Husby G. Wegener's granulomatosis: long-term follow-up of patients treated with pulse cyclophosphamide. Br J Rheumatol 1998;37:659-64.
23. Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998;41:1835-44.
24. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
25. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997;90:401-9.
26. Carette S, Klippel JH, Decker JL, Austin HA, Plotz PH, Steinberg AD, et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med 1983; 99:1-8.
27. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
28. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997;56:481-7.
29. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
30. Gøransson LG, Brodin C, Ogreid P, Janssen EA, Romundstad PR, Vatten L, et al. Intravenous cyclophosphamide in patients with chronic systemic inflammatory diseases: morbidity and mortality. Scand J Rheumatol 2008;37:130-4.
31. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70.
32. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20:838-44.
33. Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995;38:1120-7.
34. Le Guenno G, Mahr A, Pagnoux C, Dhote R, Guillevin L; French Vasculitis Study Group. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011;63:1435-45.
35. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 1971;285:1493-6.
36. Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med 1971;284:938-42.
37. de Groot K, Adu D, Savage CO; EUVAS (European vasculitis study group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001;16:2018-27.
38. Boumpas DT, Illei GG, Balow JE. Treatment: renal involvement. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology, 3rd ed. Edinburgh: Mosby; 2003: 1405-17.
39. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-7.
40. Hows JM, Mehta A, Ward L, Woods K, Perez R, Gordon MY, et al. Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study. Br J Cancer 1984;50:753-6.
41. Shepherd JD, Pringle LE, Barnett MJ, Klingemann HG, Reece DE, Phillips GL. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1991;9:2016-20.
42. Vose JM, Reed EC, Pippert GC, Anderson JR, Bierman PJ, Kessinger A, et al. Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. J Clin Oncol 1993;11:1306-10.
43. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
44. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-57.